All News
ICYMI: 2020 Rheumatology Year in Review
2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.
Read ArticleICYMI: JAK Inhibitor Misses Endpoint in Safety Study. Now What?
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Read ArticleLinks:
RheumNow Podcast – As Good As I Ever Was (7.2.2021)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)
Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2021 – Day 4 Report
It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.
Read ArticleLinks:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
RheumNow Podcast - Best of EULAR 2021
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Read ArticleLinks:
Links:
Links:
EULAR 2021 - Day 3 Report
Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
Read ArticleIsrael provides COVID vaccine answers for rheumatic disease patients
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br
Read ArticleLinks: